GEOVAX LABS INC
GOVXNASDAQ🏆 #3730 by market capUS Equity
$0.83▲ $0.06 (+7.51%)
Live1h—
24h▲ 7.5%
7d▲ 9.5%
14d▲ 14.7%
30d▼ 29.9%
1y▼ 95.1%
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
-31.8%
Thin
💵FCF Margin
6.6%
Moderate
⚖️P/S Ratio
0.9x
Cheap
Otter Score
50
Weak
Trading Snapshot
- Day Range
- $0.82 – $0.84
- 52-Week Range
- $0.64 – $20.00
- Volume
- $3.05B
- Avg Volume
- $2.15B
- Shares Outstanding
- 7.4M
- Next Earnings
- Sep 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- 0.9x
- EPS (TTM)
- $-13.92
- Dividend Yield
- —
Why Investors Own GOVX
- ✓High-growth profile — revenue up +58.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 63% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$6M▲ +56.9% YoY
Gross Margin (TTM)
63.2%▲ +1.0% YoY
Operating Income (TTM)
$2M▲ +56.9% YoY
Free Cash Flow (TTM)
$282,581▲ +56.9% YoY
About GEOVAX LABS INC
A company profile for GEOVAX LABS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
50/100
Analyst Price Target
ⓘAverage Target
$1.05
▲ +26.2% Upside
High Target$1.14
Low Target$0.96
Based on 18 analysts
Latest News & Updates
ChartMill·15d ago
GeoVax Labs (GOVX): High Growth Stock Beats Earnings, Advances Mpox Vaccine and Cancer Therapy
GeoVax Labs (GOVX) Q2 2026 net loss of $0.97/share beat estimates by 67%, driven by cost cuts. Focus on mpox/smallpox vaccine GEO-MVA and cancer therapy Gedeptin.
🛰️
Benzinga·15d ago
Geovax Labs Q2 EPS $(0.97) Beats $(2.88) Estimate
Geovax Labs (NASDAQ:GOVX) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(2.88) by 66.32 percent. This is a 88.9 percent increase over losses of $(8.74) per share from the